Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.
McCullough A, Chen CD, Gordon BA, Joseph-Mathurin N, Jack CR Jr, Koeppe R, Hornbeck R, Koudelis D, McKay NS, Hobbs DA, Flores S, Keefe SJ, Aggarwal NT, Allegri RF, Berman SB, Bird T, Black SE, Brooks WS, Chhatwal JP, Day GS, Farlow MR, Fox NC, Gauthier S, Honig LS, Hsiung GY, Jucker M, Levin J, Masellis M, Masters C, Mendez PC, Ringman JM, Snider BJ, Salloway S, Schofield PR, Shimada H, Suzuki K, van Dyck CH, Klein G, Clifford DB, Cruchaga C, Hassenstab J, Li Y, McDade E, Mills S, Morris JC, Perrin RJ, Supnet-Bell C, Wang G, Xiong C, Bateman RJ, Benzinger TLS; DIAN‐TU Study Team.
McCullough A, et al. Among authors: mendez pc.
Alzheimers Dement. 2025 Jul;21(7):e70347. doi: 10.1002/alz.70347.
Alzheimers Dement. 2025.
PMID: 40660741
Free PMC article.
Clinical Trial.